Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Long-term oncological implications of hormone-replacement therapy in women with Kallmann syndrome: A propensity-matched study from the Global Federated Health Research Network.

Sarah Eidbo, Akshay Ratnani, Muluken Megiso et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22525

e22525 Background: Kallmann syndrome is a rare genetic condition known for its characteristic hypogonadotropic hypogonadism and anosmia. Kallmann syndrome...

Analysis of a large language model-based system versus manual review in clinical data abstraction and deduction from real-world medical records of patients with melanoma for clinical trial eligibility assessment.

Christine Vecchio, Stephanie Braley, Lucy Boyce Kennedy et al. Jun 01, 2025 pp. 1571-1571 10.1200/jco.2025.43.16_suppl.1571

1571 Background: Manual chart review (MCR) is the gold standard for assessment of information from electronic medical reco...

Barriers and facilitators to seeking care for the initial diagnosis of melanoma in an urban safety-net hospital.

Yaelle Shaked, Alyssa Swearingen, Sophia Manduca et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23123

e23123 Background: Unlike locally advanced melanoma, early-stage melanoma is highly curable. Yet, despite increased efforts that promote recognition of ea...

Safety and efficacy of a small-molecule c-Myc degrader WBC100 in solid tumors: A first-in-human, phase I trial.

Qi Zhang, Qihan Fu, Hongkan Wang et al. Jun 01, 2025 pp. 3120-3120 10.1200/jco.2025.43.16_suppl.3120

3120 Background: c-Myc amplification or overexpression is involved in the development and progression of many human cancers, and is often asso...

A quality initiative focused on biomarker testing in stage IB-IIIA resected and stage IV non-small cell lung cancer patients.

Brian Patrick Mulherin, Taral H Patel, Jeffrey Alan Scott et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13563

e13563 Background: The NCCN guidelines recommend non-small cell lung cancer (NSCLC) patients (pts) who are stage IB-IIIA (E-Stg) who have been resected to...

Concordance of parent-of-origin predictions for hereditary cancer variants using proband-only analysis.

Lilian Cordova, Vahid Akbari, Tiffany Leung et al. Jun 01, 2025 pp. 10595-10595 10.1200/jco.2025.43.16_suppl.10595

10595 Background: Determining the parental origin of germline variants is a critical gap in clinical genetics, essential for risk management, variant clas...

Evaluating generative AI models for development of patient education quizzes on hormone-related symptoms of cancer therapy.

Claire Dvorak, Jeffrey R Smith, Nikita C. Shah et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13880

e13880 Background: To assess whether generative AI models can effectively design patient-appropriate educational quizzes on hormone-related symptoms of ca...

Prognostic significance of preoperational circulating tumor DNA detection in early-stage NSCLC using a tissue-free blood test.

Naixin Liang, Zhicheng Huang, Jiayue Xu et al. Jun 01, 2025 pp. 3045-3045 10.1200/jco.2025.43.16_suppl.3045

3045 Background: There is a growing need for risk evaluation and treatment monitoring in cancer care. However, current methods, mainly imaging, can be bur...

Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.

Anwaar Saeed, Jun Zhang, Babar Bashir et al. Jun 01, 2025 pp. 3517-3517 10.1200/jco.2025.43.16_suppl.3517

3517 Background: DSP107 is a bi-specific fusion protein composed of sequences from the extracellular domain of SIRPα and 4-1BBL. The SIRPα arm selectively...

Health-related quality of life in metastatic hormone sensitive prostate cancer (mHSPC): Insights from a network meta-analysis of treatment options.

Neal D. Shore, Noman Paracha, Howard Thom et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17092

e17092 Background: Health-related quality of life (HRQoL) directly impacts both disease control outcomes and the patient experience playing a significant...

MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis.

Ibrahim Aldoss, Pankit Vachhani, Hagop M. Kantarjian et al. Jun 01, 2025 pp. 6510-6510 10.1200/jco.2025.43.16_suppl.6510

6510 Background: The phase 3 PhALLCON trial (NCT03589326) in adults with newly diagnosed Ph+ ALL met its primary endpoint, showing a significantly higher...

Clinical characteristics, molecular landscape and survival outcomes of metastatic pancreatic cancer from western India.

Kunal Naishadh Jobanputra, Kshitij Joshi, Udip Maheshwari et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16401

e16401 Background: Pancreatic cancer is an aggressive malignancy often diagnosed at an advanced, metastatic stage, leading to poor prognosis....

Safety and efficacy of sintilimab versus pembrolizumab in the treatment of advanced or recurrent pediatric malignancies: A real-world study in China.

Lei Mao, Juan Wang, Mengjia Song et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22010

e22010 Background: PD-1 inhibitors have shown durable response and mild adverse events in adult malignancies. Studies of a direct comparison of distinct P...

Trastuzumab deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) with active CNS metastases: Real world data.

Lyudmila Zhukova, Irina Bykonya, Maria Rodina et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13024

e13024 Background: T-DXd is considered one of the promising agents for the treatment of HER2+ ABC including patients (pts) with metastases (mts) to the CN...

Barriers and challenges for precision medicine and evidence-based oncology in genitourinary tumors in Latin America: insights from the LACOG 1024 survey CIELO.

Daniel Vargas Pivato de Almeida, Melissa Kluver, Carolina Passarella et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23041

e23041 Background: Precision medicine and evidence-based oncology are cornerstones of modern cancer care, enabling personalized treatment strategies. Howe...

Testosterone replacement therapy for fatigue, sexual dysfunction, and quality of life in older men with cancer (TEMEC).

Egidio Del Fabbro, Shehzad Basaria, Donna L Berry et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps12138

TPS12138 Background: Fatigue is prevalent in men with cancer, affecting 70-100% of survivors. Fatigue impairs quality of life (QOL), increases caregiver b...

Sintilimab plus bevacizumab, oxaliplatin, and capecitabine as perioperative therapy in microsatellite-stable, resectable colorectal cancer liver metastases: An open-label, single-arm, phase II trial.

Yu-hong Li Jun 01, 2025 pp. 3586-3586 10.1200/jco.2025.43.16_suppl.3586

3586 Background: Immunotherapy has revolutionized cancer treatment, yet its efficacy in proficient mismatch repair and/or microsatellite stable (pMMR/MSS)...

A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve (TN) chronic lymphocytic leukemia (CLL).

Mazyar Shadman, Keri Yang, Sheng Xu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19031

e19031 Background: While the efficacy of zanubrutinib (ZANU) has been evaluated in the phase 3 SEQUOIA trial (NCT03336333), and the combination regimen of...

Efficacy and safety of donafenib combined with interventional therapy and with/without immunotherapy in hepatocellular carcinoma: A retrospective study.

Hui Li, Baojiang Liu, Xu Zhu Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16177

e16177 Background: The Phase III clinical trial ZGDH 3 and several real-world studies have demonstrated the potential of Donafenil to improve overall surv...

Physical rehabilitation program for cardiorespiratory health and quality of life among breast cancer survivors: A randomized control trial.

Fatima Abdul Rashid, Wajiha Anwar, Praveen Kumar Kandakurti et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12500

e12500 Background: Breast cancer treatment has improved significantly, contributing to a 5-year relative survival rate of 99% for localized cases. However...

Disparities in time to completion of multi-target stool DNA testing: A retrospective study across a statewide population.

Arup Ganguly, Vaidarshi Abbagoni, Ruchir Paladiya et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13762

e13762 Background: Colorectal cancer screening using non-invasive methods like the multi-target stool DNA test(Exact Sciences, Madison, WI) is an emerging...

Camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): 1-year outcomes from the phase II trial.

Dongmei ji, Youzhou Sang, Yanan Yang et al. Jun 01, 2025 pp. 6030-6030 10.1200/jco.2025.43.16_suppl.6030

6030 Background: Pembrolizumab or cetuximab combined with platinum-based-chemo are standard first-line regimen for R/M HNSCC, but the efficacy is far from...

Lighting up PNET: Creating murine models with a novel bioluminescent cell line.

Rachel Nation, Matthew Christopher Moccia, T Hess et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16352

e16352 Background: Pancreatic neuroendocrine tumors (PNETs) are rare malignancies characterized by dysregulation of complex molecular signaling pathways....

Splicing factor 3B subunit 1A (SF3B1) mutations in lymphoid malignancies.

Rahul Chowdhary, Kirti Arora, Jahanvi Grover et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23315

e23315 Background: Advancements in genetic profiling are paving the way to personalized medicine by identification of mutations across all tumor types, he...

Actionable insights: Liquid NGS in community oncology practice.

Raj N. Shah, Quoc Van Truong, Fady El Tom et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15081

e15081 Background: Liquid-based next-generation sequencing (NGS) is an integral test alongside tissue biopsy for identifying actionable mutations in vario...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page